Compass Q3 net loss $10.0M ($0.08/shr); cash $164M; CEO succession to Bisker-Leib

Compass Therapeutics, Inc.

Net loss for Q3 2023 was $10.0M ($0.08/shr) vs $12.0M ($0.12/shr) in Q3 2022; 9-month net loss $29.1M.
Cash and marketable securities $164M as of Sep 30, 2023, providing cash runway into 2026.
CEO succession: President/COO Vered Bisker-Leib to become CEO; current CEO Thomas Schuetz to President of R&D and Vice Chair, effective Jan 9, 2024.
CTX-009 Ph2/3 COMPANION-002 (BTC) top line data expected H2 2024; initial data from COMPANION-003 (CRC) expected by year-end 2023.
CTX-8371 IND cleared; Phase 1 trial to start Q4 2023. CTX-471 dose-escalation completed; expansion expected Q1 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Compass Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income Net loss for the third quarter ended September 30, 2023 was $10.0 million or $0.08 per common share, EPS $0.08 per common share.

Period: third quarter ended September 30, 2023
Net income: Net loss for the third quarter ended September 30, 2023 was $10.0 million or $0.08 per common share
EPS: $0.08 per common share
Result: reported results

Exact text from the filing

On November 9, 2023, Compass Therapeutics, Inc. issued a press release announcing financial results for the third quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Compass Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-006911

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.